GlassScriptPhysician profile
Sumera Pervaiz
NPI 1619382009
$2,200.26
in general payments reported to CMS, 2019-2025
28 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.34 · 2020: $145 · 2021: $144 · 2022: $558 · 2023: $439 · 2024: $513 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.78 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $482.53 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $191.71 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $176.59 | 2020-2024 | Airsupra, Farxiga |
| Pfizer INC. | $173.99 | 2020-2025 | |
| Lilly USA, LLC | $171.27 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $140.84 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $96.79 | 2021-2024 | Rexulti |
| Inspire Medical Systems, INC. | $93.59 | 2024-2025 | Inspire |
| Exact Sciences Corporation | $90.92 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $73.55 | 2023-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $71.81 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Gilead Sciences, INC. | $65.72 | 2019-2020 | |
| Dexcom, INC. | $61.85 | 2022-2024 | Dexcom G6 Transmitter |
| Linus Health, INC. | $37.46 | 2022-2023 | |
| Medtronic, INC. | $33.76 | 2024 | Intellis Adaptivestim, Interstim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $27.78 | 2025 | Neffy |
| Corium, LLC | $24.36 | 2023 | Azstarys |
| Eisai INC. | $23.80 | 2019 | |
| Ibsa Pharma INC. | $22.60 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $21.77 | 2025 | |
| Philips North America LLC | $18.18 | 2024 | (Ck7) Extended Holter |
| Vital Connect, INC | $18.18 | 2022 | |
| Aytu Biopharma, INC. | $17.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.59 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $14.09 | 2019 | |
| Amgen INC. | $11.96 | 2019 | |
| Qiagen, LLC | $11.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumera Pervaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.